{"id":"spm-962","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By selectively inhibiting S1PR1, SPM 962 is expected to reduce the number of circulating lymphocytes, thereby reducing inflammation and potentially treating autoimmune diseases. This mechanism of action is distinct from other S1P receptor modulators, which often have a broader range of activity and may have different safety profiles.","oneSentence":"SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:56.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00244387","phase":"PHASE3","title":"Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-03","conditions":"Parkinson Disease, Idiopathic","enrollment":506},{"nctId":"NCT00243971","phase":"PHASE3","title":"A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-11","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01084551","phase":"PHASE3","title":"Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-02","conditions":"Idiopathic Restless Legs Syndrome","enrollment":284},{"nctId":"NCT01628926","phase":"PHASE3","title":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-06","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT01737931","phase":"PHASE1","title":"A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-08","conditions":"Healthy","enrollment":120},{"nctId":"NCT00666965","phase":"PHASE2","title":"A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-06","conditions":"Idiopathic Restless Legs Syndrome","enrollment":230},{"nctId":"NCT01562743","phase":"PHASE2","title":"A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-08","conditions":"Idiopathic Restless Legs Syndrome","enrollment":185},{"nctId":"NCT01631812","phase":"PHASE2","title":"A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2006-12","conditions":"Parkinson's Disease","enrollment":130},{"nctId":"NCT01631825","phase":"PHASE3","title":"A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-10","conditions":"Parkinson's Disease","enrollment":321},{"nctId":"NCT01628965","phase":"PHASE2, PHASE3","title":"A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-01","conditions":"Parkinson's Disease","enrollment":143},{"nctId":"NCT01634243","phase":"PHASE2","title":"A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2005-01","conditions":"Parkinson's Disease","enrollment":64},{"nctId":"NCT00537485","phase":"PHASE2, PHASE3","title":"A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-09","conditions":"Early Parkinson's Disease","enrollment":180},{"nctId":"NCT01628848","phase":"PHASE2","title":"A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2006-08","conditions":"Parkinson's Disease","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rotigotine"],"phase":"phase_3","status":"active","brandName":"SPM 962","genericName":"SPM 962","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}